# Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

> **NCT02175186** · PHASE4 · COMPLETED · sponsor: **Young-Hak Kim, MD, PhD** · enrollment: 47 (actual)

## Conditions studied

- Gastritis
- Gastroduodenal Ulcer

## Interventions

- **DRUG:** ALBIS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02175186
- **Lead sponsor:** Young-Hak Kim, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-21
- **Primary completion:** 2018-12-01
- **Final completion:** 2019-01-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175186, "Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02175186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*